A large majority of the comments/questions we receive from our readers are requests for recommendations for a PAH expert close to home. This is a very important question that is very difficult to answer. Pulmonary arterial hypertension is a rare disease, community physicians may not know of any PH specialists in their area. … [Read more...]
Archives for November 2013
FDA Approves Changes to the Letairis REMS Program
In August 2013 the FDA (Food and Drug Administration) approved changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program. Letairis is an oral ERA originally approved by the FDA for treatment of pulmonary arterial hypertension in 2007. … [Read more...]